Does Retatrutide Affect Libido? What the Data Show and What They Miss
A research-focused answer to "Does Retatrutide Affect Libido? What the Data Show and What They Miss". What the evidence can establish, its limits, and retatrutide's investigational status.
FormBlends Editorial Research · Updated 2026-09-27
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Reading the trial record
In the 2023 phase 2 obesity trial, 338 adults were randomized to retatrutide groups or placebo and followed for 48 weeks. The reported mean weight reduction at 48 weeks was 24.2% in the highest target-dose group and 2.1% in the placebo group. These are group averages from that study, not an individual forecast or a result from TRIUMPH-1.
Benefits must be considered alongside adverse events and withdrawals. The publication reported dose-related gastrointestinal events and increases in heart rate. The study does not establish long-term safety, outcomes after indefinite use or a consumer treatment plan. Individual photographs and social-media accounts cannot substitute for controlled evidence.
NCT04881760 is the phase 2 obesity registration. TRIUMPH-1 is NCT05929066; TRIUMPH-3 is NCT05882045. TRIUMPH-4 concerns obesity with knee osteoarthritis. A sponsor announcement, registry results and a peer-reviewed publication should be identified separately, with their dates and study populations.
How to evaluate a claim about this topic
The question "Does Retatrutide Affect Libido? What the Data Show and What They Miss" needs evidence that matches the actual claim. Identify the named study, the population enrolled and the outcome measured. Check whether the result was prespecified, whether there was a relevant comparator, and whether the report includes harms as well as benefits. The studies linked below provide context; they do not establish every claim implied by this question.
Sources
Questions about retatrutide evidence and trials
Readers researching sexual desire changes on retatrutide often encounter early trial data. Here is what regulatory records and clinical registries currently verify.
What outcomes were evaluated in retatrutide phase 2 clinical trials?
In a completed phase 2 trial of 338 participants with overweight or obesity, registry outcomes measured mean percent change in body weight, change in BMI, and waist circumference across 24 and 48 weeks. A second completed phase 2 trial of 281 adults with type 2 diabetes evaluated changes in HbA1c, fasting blood glucose, and body weight.
How much clinical research has been published on retatrutide?
ClinicalTrials.gov lists 34 registered studies for retatrutide, with 3 posting results and 14 in phase 3. Across scientific literature, PubMed lists 222 papers on retatrutide, including 136 human studies and 11 randomized controlled trials, with 220 published since 2023.
Sources: ClinicalTrials.gov and PubMed counts (accessed 2026-11-16); ClinicalTrials.gov, NCT04867785 (accessed 2026-11-16); ClinicalTrials.gov, NCT04881760 (accessed 2026-11-16); FDA: concerns with unapproved GLP-1 drugs used for weight loss (accessed 2026-11-16)